CDx Diagnostics Continues to Shine with Strong Data

A newly published study of CDx Diagnostics’s WATS3D, which employs artificial intelligence (AI), continues to show the effectiveness of the test for the detection Barrett’s esophagus. The nearly 13,000-patient study was published in Diseases of the Esophagus. The results come right in the middle of the AI Renaissance that is occurring in healthcare. The Suffern, NY-based company’s published data showed that the addition of WATS3D to standard targeted and random forceps biopsy (FB) markedly increases the overall detection of esophageal dysplasia by 242% and the overall detection of Barrett’s esophagus by 153% in patients undergoing screening and surveillance. “The [study results] are a validation of what we have known for a long time,” Michael S. Smith, MD, MBA, lead author and Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai St. Luke's Hospitals in New York City, told MD+DI. “And that is the four quadrant Seattle protocol forceps biopsy method of following a patient who has Barrett’s or examining a patient where there is concern for Barrett’s is simply an inadequate approach to managing this disease.” He added, that through WATS3D there is a better way to “effectively monitor and follow this precancerous condition of the esophagus that goes well beyond w...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Imaging Source Type: news